Of course, two downthumbs I got on my post above shows that the WS crooks reside on this board and not all visitors of this board are just poor retail traders!!!
Mail, there is one advantage to management members for keeping the SP low: They can award themselves cheaply priced stock options!! BlackM doesn't seem to have considered that!!!
Black, your complaints to change the management done through hundreds of your posts on this board has none and will have no effect and you know that very well. If after committing almost a billion dollars, J&J doesn't want to replace Scarlett, your vocal expression of frustration is not going to help. So too if the funds that hold millions of shares in this company do not want any management change at this point, Scarlett is a fact of life for us retail shareholders. Then why are you wasting all your efforts? In my view, you have no choice as an insignificant shareholder, like I am, but to live with what we got!! It's fruitless to keep hammering the same point and get unnecessary headaches..
Also, IWS, traditionally, the SP doesn't get lifted substantially until Ph 3 for clinical stage biotechs. In Geron's case , due to JNJ involvement, it may happen earlier if an FTD or BTD status is granted. I do not expect that before well into Ph 2 of the MF trial and other evidences are gathered that show that IMET will have potentially lucrative multiapplications. Until then, WS dogs who are seasoned manipulators will keep playing the stock to make some money while many fools on this board keep speculating passing on stupid theories of their own!!
rattlebug, while you are theoretically right, you are living in a dream world if you believe that there is no manipulation by WS crooks and that that has a prominent effect on the current trading and SP of Geron!!
terrier, thanks for elaborating what I really stated in my original post. This is not a game played by retail traders, it's being played by WS crooks. And, neither SEC nor you are going to stop it!! Just live with these jerks!!
The stock trading is manipulated currently to keep the SP low so that those given chance to accumulate will get a decent profit when the SP jumps up, perhaps within a month and when the shorts rush frantically to cover. All other talk and Bollinger-band or wedge theory garbage doesn't apply to overall trading of this stock. WS controls and not mom-and-pop trader!!
Oops, please correct my spelling of pundit in my posts above. Thanks.
Of course, I am no pundit myself!!!
A pandit is an expert, having deep knowledge and understanding and has developed intuitive ability.
Do you really understand the difference between various types of stem cells?? The way you express it in your post, it appears to me that your understanding is that stem cells are just like a Sear's wrench!!!
The 8-K was filed a month BEFORE the deal with Janssen was announced!! The waiting period for the agreement was cvut short by the FTC and Geron HAS the first instalment of $35M from J&J!!
I see a lot of semi-pandits trying to figure out what is going on at Geron and trying to tie the current lackluster SP performance to some kind of developing news!! All are talking like four blind persons describing an elephant. And, the discussions are taken seriously by those who do not have any idea about what IMET really is, what really is the deal with Janssen and why has J&J decided to agree to give as much as $900M to Geron . I am having fun watching all the gossip!!! And, my God, it's even fun watching Irish Trader becoming a standard bearer and source for authentic news about what IMET is doing!! I urge all really interested guys looking for real answers to read the facts from the right sources and use their common sense to weigh the facts. And, for God's sake, do not act like Pandits!!!
Must be a hedge fund which has the MM in its pocket. Is this WS dog incapable of finding any other stock to do so?!!! Perhaps he afraid of getting caught by the SEC!!!
pretty soon!! They are flocked now on EXEL, meaning where the action is. I think, they should take a break in their mad rush for easy money and join forces to wage a ground war against ISIS - a badly needed human service that will give them reason to go to heaven with some lives-saving accomplishments and sense of satisfaction for being on this earth, especially in our country!! Doing some constructive work and sacrifice in life are a necessary thing to go to heaven, otherwise, they will keep rotting on this earth for several lives!!!
That is a good possibility, like Geron did, because the RPE technology and its application to SMD and AMD are likely to be a brilliant success. Thus, Ocata must have found a compatible partner with large pockets who is interested in it and can help bring about the FDA's consent for a BTD status fast, again just like Geron finding J&J to push its IMET. I think these shares are a good candidate currently for adding to your portfolio if you have money to invest. At least, I will not think of divesting. I will be a fool to do so!!
These successful rich guys hire experts and knowledgeable specialists for building the funds they invest their money into. Meaning, if these funds invest substantial amounts or a substantial percentage of shares of a company, that decision is not taken without an exhaustive study. In short, if they have a substantial interest in Geron as shown through the filing(s), there is a pretty good chance that Geron shares are an attractive investment. I will not read it beyond that!! And, for me, it's sufficient to know and feel assured of my investment in Geron. I will not be a fool, if I am a retail short, to keep shorting it!! The real puzzle is who really are the people shorting 30M shares of Geron? Are they fools too?
Thanks, Vette. If '615 is based on IMET or is an extension of IMET, it may have been included in the deal indirectly. If so, Janssen may legally be able to bring up clarification issue. And, if so, Geron can not afford to antagonize Janssen. Geron, being just a 46-employee outfit, needs a cooperative hand from Janssen. Perhaps, this new drug can bring Geron's merger with Janssen (if that is the final step) a more favorable deal. It will be interesting to know if Tefferi's contract is limited only to the MF/MDS/AML trials or goes beyond it? Tefferi's other responsibilities at Mayo may allow him to devote only a limited effort and his deeper involvement may result in his accepting a position, most likely, with Janssen. If so, his loyalty to Janssen will force him to cooperate with Janssen rather than with Geron. What I mean is that all these factors may force Geron to remain amiable to Janseen than go against it, unless Geron has an another large pharma up its sleeve (which I doubt).